Sean Agbor-Enoh
Overview
Explore the profile of Sean Agbor-Enoh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
764
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Jang M, Markowitz T, Andargie T, Apalara Z, Kuhn S, Agbor-Enoh S
bioRxiv
. 2023 Feb;
PMID: 36789421
Patient monitoring is a cornerstone in clinical practice to define disease phenotypes and guide clinical management. Unfortunately, this is often reliant on invasive and/or less sensitive methods that do not...
22.
Keller M, Yang S, Ponor L, Bon A, Cochrane A, Philogene M, et al.
Am J Transplant
. 2023 Feb;
23(4):559-564.
PMID: 36732088
The development of donor-specific antibodies after lung transplantation is associated with downstream acute cellular rejection, antibody-mediated rejection (AMR), chronic lung allograft dysfunction (CLAD), or death. It is unknown whether preemptive...
23.
Charya A, Ponor I, Cochrane A, Levine D, Philogene M, Fu Y, et al.
J Heart Lung Transplant
. 2022 Nov;
42(2):226-235.
PMID: 36319530
Background: Pulmonary antibody-mediated rejection (AMR) consensus criteria categorize AMR by diagnostic certainty. This study aims to define the clinical features and associated outcomes of these recently defined AMR categories. Methods:...
24.
Keller M, Charya A, Andargie T, Agbor-Enoh S
Clin Chem
. 2022 Oct;
68(11):1368-1373.
PMID: 36226752
No abstract available.
25.
Brusca S, Elinoff J, Zou Y, Jang M, Kong H, Demirkale C, et al.
Circulation
. 2022 Aug;
146(14):1033-1045.
PMID: 36004627
Background: Cell-free DNA (cfDNA) is a noninvasive marker of cellular injury. Its significance in pulmonary arterial hypertension (PAH) is unknown. Methods: Plasma cfDNA was measured in 2 PAH cohorts (A,...
26.
Pang Y, Charya A, Keller M, Sirajuddin A, Fu Y, Holtzman N, et al.
Blood Adv
. 2022 Jul;
6(17):4987-4988.
PMID: 35882499
No abstract available.
27.
Shah P, Agbor-Enoh S, Bagchi P, deFilippi C, Mercado A, Diao G, et al.
J Heart Lung Transplant
. 2022 Jul;
41(10):1401-1413.
PMID: 35872109
Background: Noninvasive monitoring of heart allograft health is important to improve clinical outcomes. MicroRNAs (miRs) are promising biomarkers of cardiovascular disease and limited studies suggest they can be used to...
28.
Bazemore K, Permpalung N, Mathew J, Lemma M, Haile B, Avery R, et al.
Am J Transplant
. 2022 Jun;
22(11):2560-2570.
PMID: 35729715
Respiratory viral infection (RVI) in lung transplant recipients (LTRs) is a risk for chronic lung allograft dysfunction (CLAD). We hypothesize that donor-derived cell-free DNA (%ddcfDNA), at the time of RVI...
29.
Keller M, Agbor-Enoh S
Curr Opin Organ Transplant
. 2022 Jun;
27(3):177-183.
PMID: 35649108
Purpose Of Review: Recent evidence indicates that plasma donor-derived cell-free DNA (dd-cfDNA) is a sensitive biomarker for the detection of underlying allograft injury, including rejection and infection. In this review,...
30.
Pang Y, Charya A, Keller M, Sirajuddin A, Fu Y, Holtzman N, et al.
Blood Adv
. 2022 May;
6(14):4196-4207.
PMID: 35522969
Pulmonary chronic graft-versus-host disease (PcGVHD) is a devastating complication of allogeneic hematopoietic stem cell transplant (HCT). The 2014 National Institutes of Health cGVHD consensus criteria (NIH criteria) only captures bronchiolitis...